KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Exact Sciences (EXAS) Gains from Investment Securities (2016 - 2025)

Exact Sciences (EXAS) has disclosed Gains from Investment Securities for 16 consecutive years, with -$22.1 million as the latest value for Q3 2025.

  • On a quarterly basis, Gains from Investment Securities fell 515.5% to -$22.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$6.5 million, a 132.93% decrease, with the full-year FY2023 number at $16.6 million, down 61.32% from a year prior.
  • Gains from Investment Securities was -$22.1 million for Q3 2025 at Exact Sciences, down from $15.2 million in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $78.6 million in Q3 2022 to a low of -$53.0 million in Q2 2022.
  • A 5-year average of $5.1 million and a median of $2.3 million in 2024 define the central range for Gains from Investment Securities.
  • Biggest YoY gain for Gains from Investment Securities was 13970.72% in 2021; the steepest drop was 10180.0% in 2021.
  • Exact Sciences' Gains from Investment Securities stood at $48.5 million in 2021, then plummeted by 67.05% to $16.0 million in 2022, then grew by 17.25% to $18.8 million in 2023, then tumbled by 87.6% to $2.3 million in 2024, then plummeted by 1048.54% to -$22.1 million in 2025.
  • Per Business Quant, the three most recent readings for EXAS's Gains from Investment Securities are -$22.1 million (Q3 2025), $15.2 million (Q2 2025), and -$2.0 million (Q1 2025).